Literature DB >> 10353340

Inhibition of nicotine-induced hippocampal norepinephrine release in rats by alpha-conotoxins MII and AuIB microinjected into the locus coeruleus.

Y Fu1, S G Matta, J M McIntosh, B M Sharp.   

Abstract

Hippocampal norepinephrine (NE) is secreted by neurons projecting from the locus coeruleus (LC) to the hippocampus; LC nicotinic receptors (NAchRs) are involved in the effects of systemic nicotine on this pathway. To clarify the NAchR subtypes, NAchR antagonists, termed alpha-conotoxins, were microinjected into the LC before nicotine; MII and AuIB were used to assess the potential involvement of alpha3beta2 and alpha3beta4 subunit-containing NAchRs, respectively. Nicotine dose-dependently stimulated hippocampal NE release (P < 0.01). MII (>0.25 pmol) reduced the NE response to nicotine (67% decrease; P < 0.05), as did AuIB (44% reduction by 25 pmol; P < 0.05). Administered together, however, MII and AuIB were no more effective than MII. Thus, MII and AuIB are capable of interacting with NAchR subtypes other than those previously defined as alpha3beta2 and alpha3beta4, respectively. NAchRs containing both beta2 and beta4-subunits may be involved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353340     DOI: 10.1016/s0304-3940(99)00293-1

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

2.  The α3β4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies.

Authors:  P P Muldoon; K J Jackson; E Perez; J L Harenza; S Molas; B Rais; H Anwar; N T Zaveri; R Maldonado; U Maskos; J M McIntosh; M Dierssen; M F Miles; X Chen; M De Biasi; M I Damaj
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  Native α6β4* nicotinic receptors control exocytosis in human chromaffin cells of the adrenal gland.

Authors:  Alberto Pérez-Alvarez; Alicia Hernández-Vivanco; J Michael McIntosh; Almudena Albillos
Journal:  FASEB J       Date:  2011-09-14       Impact factor: 5.191

4.  The α3β4* nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse.

Authors:  Kia J Jackson; Sarah S Sanjakdar; Pretal P Muldoon; J Michael McIntosh; M Imad Damaj
Journal:  Neuropharmacology       Date:  2013-02-13       Impact factor: 5.250

Review 5.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

Review 6.  Guidelines on nicotine dose selection for in vivo research.

Authors:  Shannon G Matta; David J Balfour; Neal L Benowitz; R Thomas Boyd; Jerry J Buccafusco; Anthony R Caggiula; Caroline R Craig; Allan C Collins; M Imad Damaj; Eric C Donny; Phillip S Gardiner; Sharon R Grady; Ulrike Heberlein; Sherry S Leonard; Edward D Levin; Ronald J Lukas; Athina Markou; Michael J Marks; Sarah E McCallum; Neeraja Parameswaran; Kenneth A Perkins; Marina R Picciotto; Maryka Quik; Jed E Rose; Adrian Rothenfluh; William R Schafer; Ian P Stolerman; Rachel F Tyndale; Jeanne M Wehner; Jeffrey M Zirger
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

7.  Involvement of alpha1-adrenergic receptors in tranylcypromine enhancement of nicotine self-administration in rat.

Authors:  Anne-Sophie Villégier; Shahrdad Lotfipour; James D Belluzzi; Frances M Leslie
Journal:  Psychopharmacology (Berl)       Date:  2007-05-08       Impact factor: 4.415

8.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.